Flare

ACE Cash Express Teams Up with The Humane Society Raising Over $75,000 to End Suffering for All Animals

Retrieved on: 
Wednesday, May 17, 2023
Patent, Public affairs, Senior, Humane Society of the United States, HSUS, Saint Andrew's Society, Jefferson Literary and Debating Society, ACE Cash Express, FDIC, Populus, Visa, Mobile app, Education Business Partnership, Animal, Flare, ACE, Porte, Humane society, Online shopping, Payment card

Last year, the Flare Account® Humane Society of the United States Debit Card1 and Porte's™ DoorToChange2 charitable giving program raised $75,372.

Key Points: 
  • Last year, the Flare Account® Humane Society of the United States Debit Card1 and Porte's™ DoorToChange2 charitable giving program raised $75,372.
  • The Humane Society of the United States fights the big fights to end suffering for all animals.
  • Through their rescue, response, and sanctuary work, as well as other hands-on animal care services, they help thousands of animals every year.
  • HSUS fights all forms of animal cruelty to achieve the vision behind their name: a humane society.

MHz Choice adds to its collection of French Agatha Christie series with the colorful entrance of 'Agatha Christie's Criminal Games: The '70s'

Retrieved on: 
Wednesday, May 17, 2023
Panic, Psychology, Heart, Male, Flare, Archive, Hertz, Face, Choice, Certification, Licensure, and Credentialing for the New Nurse Practitioner in Wisconsin, Season, Beta (film), Woman, Drama, Kino, Beretta, Patient, Nursing, Luigi Robecchi Bricchetti, Fabrizio Bentivoglio, Female, Entertainment

WASHINGTON, May 17, 2023 /PRNewswire/ -- All characters arrive in impeccable style in the newest French TV adaptation of Agatha Christie novels in MHz Choice's Agatha Christie's Criminal Games: The '70s. Collars are wide, sunglasses are huge and flares are everywhere. Captain Annie Gréco (Emilie Gavois-Kahn) shows up at the Lille police department as its first female captain. The chauvinism is ever-present even as Gréco immediately runs circles around her hapless male underlings. She acquires her first trusted investigative partner with the unlikely Max Beretta (Arthur Dupont), who was marooned in the archives after some hothead behavior following a perceived slight by a colleague. He's always a hair-trigger away from throwing a punch (or worse) but he's observant and motivated. Rose Bellacour (Chloé Chaudoye) rounds out the mismatched trio as a gifted amateur psychologist. Her outfits may scream peak 1970s fashion, but her mind is built for a more modern age. Rose is rich and doesn't technically need a job, but she's too smart to settle for being a rich guy's wife.

Key Points: 
  • WASHINGTON, May 17, 2023 /PRNewswire/ -- All characters arrive in impeccable style in the newest French TV adaptation of Agatha Christie novels in MHz Choice's Agatha Christie's Criminal Games: The '70s.
  • He's always a hair-trigger away from throwing a punch (or worse) but he's observant and motivated.
  • Rose is rich and doesn't technically need a job, but she's too smart to settle for being a rich guy's wife.
  • Also debuting this June on MHz Choice are a pair of limited series where motives are not always what they seem.

WHAT'S NEW: 2024 LC 500 Convertible

Retrieved on: 
Wednesday, May 17, 2023
Dark, Shift, Cloud, Wi-Fi, Travel, Life, Safety, USB, Temperature, SOS, POI, DPH, AVS, Adaptive cruise control, Convertible, MSRP, LC, Noise, Atmosphere, Torque, Diaphragm, Human, Acoustical Society of America, Android, Lexus, Element, HVAC, Map, Apple, White, Toyota Electronic Modulated Suspension, Safety Connect, Carbon, LTA, LFA, RSA, Radar, PCS, The Fire in Our Throats Will Beckon the Thaw, MID, Automatic parking, Harman Connected Services, HD, OTA, Black, Marketing, Movement, LDA, Wind, Sale, Flare, Coupe, Amazon Music, NUMMI, Weather, Army Foreign Intelligence Assistance Program, Paint, Electric motor, Heating, ventilation, and air conditioning, Road, Mobile phone, Sand, V8, Caviar

The LC 500 Convertible may be based in part on the LC 500 coupe, but it is no mere crop-topped replica.

Key Points: 
  • The LC 500 Convertible may be based in part on the LC 500 coupe, but it is no mere crop-topped replica.
  • For 2024, the LC 500 Convertible will adopt the LC 500h's standard 21-inch forged alloy wheels with all grades receiving a new finish of gloss black with metallic accents.
  • For 2024, the LC 500 Convertible top has expanded its color choice to four colors: Black, Sand, and two colors exclusive to Bespoke Build, Dark Rose2 and Blue2.
  • The front-engine, rear-wheel-drive LC Convertible shares the same direct-injected V8 powerplant as the LC 500 Coupe.

Mymee's Personalized Trial & Care Platform Helps Autoimmune Disease Patients Reverse Flares, New Research Shows

Retrieved on: 
Tuesday, May 16, 2023
Trigger, Long COVID, Factorization of polynomials, Flare, DMARD, Elijah Cummings Lower Drug Costs Now Act, Rx, Arthralgia, Anxiety, Case Western Reserve University School of Medicine, RMD, Quality of life, Research, COVID, Pain, DMTS, DSM-IV codes, Medical director, Patient, Risk, Autoimmune disease, OTC, Joint, HIPAA, Autoimmunity, Fatigue, Pharmaceutical industry, Nursing, Medical device, Medical imaging, Birth control, Rheumatology, Quality of life (healthcare), Medicine

NEW YORK, May 16, 2023 /PRNewswire/ -- Today Mymee Inc, the pioneer in personalized trial & care for autoimmune disease & long COVID patients, announced the publication of new peer-reviewed research in RMD Open. The study found that autoimmune disease and Long COVID patients with moderate to severe symptoms achieved statistically significant, clinically meaningful improvements in all10 PROMIS® Health-Related Quality of Life (HRQoL) domains.

Key Points: 
  • The bigger challenge is that >65% of rheumatic patients have inadequate response to autoimmune drugs in the real world.
  • The personalized trial process helps patients directly correlate symptoms to triggers, add back activities, manage sensitivities and adjust drugs with their physician, if necessary.
  • Key characteristics and findings from Mymee's personalized trial research included:
    Reversing flares: >85% of patients with moderate to severe symptoms saw improvements in HRQoL.
  • For more information on Mymee's research and personalized trial & care platform to help autoimmune Rx non-responders reverse uncontrolled flares, please visit www.mymee.com

Flare Therapeutics Named to Inc. Magazine's Annual List of Best Workplaces for 2023

Retrieved on: 
Tuesday, May 9, 2023
Face, Culture, Workplace, Biotechnology, Cancer, Creativity, Patient, Flare, Factorization of polynomials, Growth, Therapy, 100 Best Workplaces in Europe, Management

CAMBRIDGE, Mass., May 9, 2023 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has been named to Inc. magazine's annual Best Workplaces list.

Key Points: 
  • CAMBRIDGE, Mass., May 9, 2023 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, has been named to Inc. magazine's annual Best Workplaces list.
  • The list is a result of a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture, whether operating in a physical or virtual facility.
  • "We are honored to be included in Inc. Magazine's Annual List of Best Workplaces for 2023.
  • "Being named to Best Workplaces is an honor that only a small fraction of companies have been able to claim," says Inc. editor-in-chief Scott Omelianuk.

New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights

Retrieved on: 
Monday, May 8, 2023
Lupus Foundation of America, Skin condition, GSK, Hydroxychloroquine, Rituximab, Lupus, Flare, DLE, Skin, Rash, Arthralgia, Discoid lupus erythematosus, Biogen, Scar, Woman, Rheumatology, Methotrexate, Belimumab, SLE, CLE, AstraZeneca, Psoriasis, Anifrolumab, Dermatology, Patient, Physician, Lupus nephritis, Diagnosis, Merck, FDA, Skin discoloration, Bristol Myers Squibb, Fatigue, Disease, Cosmetics, Dietary supplement, Pharmaceutical industry, Aurinia

EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE). Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.

Key Points: 
  • EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America , approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE).
  • Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.
  • – Rheumatologist
    There are currently no specific FDA-approved therapies for cutaneous lupus erythematosus (CLE) or discoid lupus erythematosus (DLE) – conditions which mostly affect women and people of color.
  • Spherix Global Insight's Market Dynamix™ Cutaneous Lupus Erythematosus service focuses on this evolving market, where a paradigm shift is expected within the next few years.

Evoke Pharma’s Real-World Healthcare Utilization Data Comparing GIMOTI® to Oral Metoclopramide to Be Presented at Digestive Disease Week (DDW) 2023

Retrieved on: 
Thursday, May 4, 2023
Flare, University, Gastroenterology, McCormick Place, Research, Gastroparesis, Abdominal pain, Associate, Stomach, Vomiting, DDW, MD, Patient, Machine learning, DGP, Nausea, Metoclopramide, FDA, Pharmaceutical industry, Medicine

SOLANA BEACH, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that the abstract entitled “Reducing Real-World Healthcare Resource Utilization For Patients With Diabetic Gastroparesis (DGP) Treated with Metoclopramide Nasal Spray Versus Oral Metoclopramide” will be presented at Digestive Disease Week (DDW) 2023 taking place from May 6-9, 2023 at the McCormick Place, Chicago.

Key Points: 
  • These real-world data were selected for presentation alongside a total of only six (6) meritorious clinical abstracts from more than 3,500 that were submitted.
  • In addition, Evoke Pharma will showcase their GIMOTI nasal spray and supporting educational materials at DDW booth #3334.
  • AGA Distinguished Plenary Presentation Title: “Reducing Real-World Healthcare Resource Utilization for Patients with Diabetic Gastroparesis (DGP)
    2.
  • Poster Presentation Title: “Use of Machine Learning to Identify Gastroparesis Patient Appropriate for Nasal Spray Metoclopramide” (Poster Number:

SAA's 5th Annual Global Spondyloarthritis Summit Empowers Patient Community with Access to Health Experts & Information

Retrieved on: 
Thursday, May 4, 2023
Flare, Diet, Genetics, Sleep, Cardiovascular disease, SAA, PDT, Spondylitis, Novartis, Patient, AbbVie, Cannabis, Disease, Nursing, Spondyloarthropathy

ENCINO, Calif., May 3, 2023 /PRNewswire-PRWeb/ -- As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis (SpA) community, the Spondylitis Association of America (SAA) will host its 5th Annual Global Spondyloarthritis Summit, May 5- 6, 2023. This year's educational program provides attendees access to 12 presentations covering advanced and introductory topics such as treatment options, diet and nutrition, genetics, sleep and spondyloarthritis, gender differences, surgery recommendations, cannabis, cardiovascular disease, flares, and more. Free access to Summit presentations begins at 9 am PDT on Friday, May 5, 2023.

Key Points: 
  • As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis community, SAA will host its 5th Annual Global Spondyloarthritis Summit, May 5- 6, 2023.
  • ENCINO, Calif., May 3, 2023 /PRNewswire-PRWeb/ -- As an integral component of its mission and ongoing commitment to providing programs to educate and empower the spondyloarthritis (SpA) community, the Spondylitis Association of America (SAA) will host its 5th Annual Global Spondyloarthritis Summit , May 5- 6, 2023.
  • Free access to Summit presentations begins at 9 am PDT on Friday, May 5, 2023.
  • "The Global Spondyloarthritis Summit is just one example of our ongoing commitment to empowering the SpA community, and we are proud to be able to offer access to this content – all at no charge," Shafer added.

Vespene Energy and Viridi Energy Launch Pilot Using Landfill Methane Emissions to Power Onsite Data Processing

Retrieved on: 
Tuesday, May 2, 2023
Electricity, Gasoline, EPA, Methane, StarCraft, Flare, Partnership, RNG, Research, NASA, Carbon, Landfill, Natural gas, Viridi

BERKELEY, Calif., May 2, 2023 /PRNewswire/ -- Vespene Energy ("Vespene"), a biogas renewable energy developer, and Viridi Energy ("Viridi"), a full-service renewable natural gas (RNG) platform, today announced the launch of their first joint pilot site with a municipal landfill in Marathon County, Wisconsin. Vespene and Viridi are using highly-efficient energy generation equipment to convert the naturally occurring landfill byproduct of methane gas into electricity that powers a variety of on-site uses, including data processing.

Key Points: 
  • Vespene and Viridi are using highly-efficient energy generation equipment to convert the naturally occurring landfill byproduct of methane gas into electricity that powers a variety of on-site uses, including data processing.
  • The pilot project will reduce greenhouse gas emissions, while generating revenue to subsidize Viridi's investment in building a state-of-the-art RNG facility at the landfill.
  • "Unlike traditional offtakers of landfill gas, Vespene's technology solution brings revenue-generating, energy-efficient data centers onsite and is immediately deployable and highly scalable," said Vespene Energy co-founder and CEO Adam Wright.
  • "This enables municipal landfill operators to monetize an otherwise stranded asset while reducing harmful greenhouse gas emissions quickly and economically."

AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

Retrieved on: 
Tuesday, May 2, 2023
Flare, Argyreia nervosa, Therapy, Week, Food, Fever, Pharmacokinetics, Șaeș, JAMA Dermatology, Pain, Congress, European Academy of Allergy and Clinical Immunology, Patient, SAN, Nausea, GPP, CGI, FDA, Recurrence, Safety, GEMINI, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Immunoglobulin G, Pharmaceutical industry, Dermatology

A potentially debilitating and life-threatening systemic inflammatory skin disease, GPP affects an estimated 15,000 to 37,000 individuals in the U.S.

Key Points: 
  • A potentially debilitating and life-threatening systemic inflammatory skin disease, GPP affects an estimated 15,000 to 37,000 individuals in the U.S.
  • Initial top-line Phase 2 study results were presented at European Academy of Dermatology and Venerology (EADV) Congress in October 2021.
  • The U.S. Food and Drug Administration granted Orphan Drug Designation to imsidolimab for the treatment of GPP in July 2020.
  • AnaptysBio announced in August 2022 that it intends to complete execution of the GEMINI Phase 3 GPP program and out license imsidolimab prior to potential FDA approval.